Your session is about to expire
← Back to Search
Pembrolizumab for B-Cell Lymphoma
Study Summary
This trial is testing the combination of two immunotherapy drugs to treat patients with a specific type of lymphoma that has returned or does not respond to treatment.
- Diffuse Large B Cell Lymphoma (DLBCL)
- Transformed B-Cell Non-Hodgkin Lymphoma
- Diffuse Large B-Cell Lymphoma
- Non-Hodgkin's Lymphoma
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You are expected to live for more than 3 months.You have received a stem cell transplant using your own cells within the last 90 days before starting the study drug.You cannot be taking any other experimental drugs at the same time.You are not eligible if you plan to have a stem cell transplant soon because it may have additional side effects when combined with mogamulizumab treatment.You have another type of cancer that is getting worse or needs treatment, except for certain types of skin cancer or early-stage cervical cancer.You have had allergic reactions to drugs that are similar to pembrolizumab or mogamulizumab.You have had or currently have a lung condition called pneumonitis that was not caused by an infection. If you needed to take steroids to treat it, you may not be eligible for the study, unless the pneumonitis was caused by chemotherapy or radiotherapy treatment and meets specific eligibility criteria.You have been treated with certain types of medications that help the immune system fight cancer before.You have received a special type of stem cell transplant called allogeneic stem cell transplant in the past.
- Group 1: Arm I (pembrolizumab, mogamulizumab)
- Group 2: Arm II (pembrolizumab)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is enrollment currently open for this research endeavor?
"As indicated on clinicaltrials.gov, enrollment for this study has been closed as of September 15th 2022 after initially being posted to the website on June 29th 2018. However, there are over three-thousand six hundred and fifty seven other trials actively accepting patients at present."
What pathologies can Mogamulizumab be employed to treat?
"Mogamulizumab can be used to deal with malignant tumours, inoperable melanoma, and cases of high microsatellite instability."
How many participants are involved in this medical trial?
"This research is currently not recruiting. It was initially uploaded on June 29th, 2018 and last modified on September 15th 2022. If you are seeking alternative studies, a search reveals that there are 2,687 trials for lymphoma (large b-cell diffuse) actively recruiting and 970 clinical trials for Mogamulizumab accepting patients."
Has Mogamulizumab been studied in any other research initiatives?
"Mogamulizumab initiated its clinical journey in 2010 at City of Hope. Thus far, 267 trials have yielded results and 970 are active with a considerable amount occurring in Montvale, New york."
How many settings are participants able to access this experiment?
"8 clinical centres are presently recruiting patients to participate in this study. Among them, Memorial Sloan Kettering Bergen in Montvale, Memorial Sloan Kettering Monmouth in Middletown and the renowned Memorial Sloan Kettering Cancer Center located within New york City can be found alongside 5 other sites."
What is the aim of this research project?
"This clinical trial will span a maximum of 6 weeks and seek to identify mogamulizumab's Maximum Tolerated Dose or Recommended Phase 2 Dosage when combined with pembrolizumab. Secondary objectives include calculating Complete Response Rate, Partial Response Rate, and Duration of Response using 95% confidence intervals and the Kaplan-Meier method respectively."
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger